Literature DB >> 20558730

Biophysical investigations of complement receptor 2 (CD21 and CR2)-ligand interactions reveal amino acid contacts unique to each receptor-ligand pair.

James M Kovacs1, Jonathan P Hannan, Elan Z Eisenmesser, V Michael Holers.   

Abstract

Human complement receptor type 2 (CR2 and CD21) is a cell membrane receptor, with 15 or 16 extracellular short consensus repeats (SCRs), that promotes B lymphocyte responses and bridges innate and acquired immunity. The most distally located SCRs, SCR1-2, mediate the interaction of CR2 with its four known ligands (C3d, EBV gp350, IFNalpha, and CD23). To ascertain specific interacting residues on CR2, we utilized NMR studies wherein gp350 and IFNalpha were titrated into (15)N-labeled SCR1-2, and chemical shift changes indicative of specific inter-molecular interactions were identified. With backbone assignments made, the chemical shift changes were mapped onto the crystal structure of SCR1-2. With regard to gp350, the binding region of CR2 is primarily focused on SCR1 and the inter-SCR linker, specifically residues Asn(11), Arg(13), Ala(22), Arg(28), Ser(32), Arg(36), Lys(41), Lys(57), Tyr(64), Lys(67), Tyr(68), Arg(83), Gly(84), and Arg(89). With regard to IFNalpha, the binding is similar to the CR2-C3d interaction with specific residues being Arg(13), Tyr(16), Arg(28), Ser(42), Lys(48), Lys(50), Tyr(68), Arg(83), Gly(84), and Arg(89). We also report thermodynamic properties of each ligand-receptor pair determined using isothermal titration calorimetry. The CR2-C3d interaction was characterized as a two-mode binding interaction with K(d) values of 0.13 and 160 microm, whereas the CR2-gp350 and CR2-IFNalpha interactions were characterized as single site binding events with affinities of 0.014 and 0.035 microm, respectively. The compilation of chemical binding maps suggests specific residues on CR2 that are uniquely important in each of these three binding interactions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20558730      PMCID: PMC2930724          DOI: 10.1074/jbc.M110.106617

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  57 in total

1.  The electrostatic nature of C3d-complement receptor 2 association.

Authors:  Dimitrios Morikis; John D Lambris
Journal:  J Immunol       Date:  2004-06-15       Impact factor: 5.422

2.  Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2).

Authors:  G R Nemerow; R Wolfert; M E McNaughton; N R Cooper
Journal:  J Virol       Date:  1985-08       Impact factor: 5.103

3.  Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis.

Authors:  J Tanner; J Weis; D Fearon; Y Whang; E Kieff
Journal:  Cell       Date:  1987-07-17       Impact factor: 41.582

4.  Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d.

Authors:  G R Nemerow; C Mold; V K Schwend; V Tollefson; N R Cooper
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

5.  Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2.

Authors:  J D Fingeroth; J J Weis; T F Tedder; J L Strominger; P A Biro; D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

6.  Identification of a partial cDNA clone for the C3d/Epstein-Barr virus receptor of human B lymphocytes: homology with the receptor for fragments C3b and C4b of the third and fourth components of complement.

Authors:  J J Weis; D T Fearon; L B Klickstein; W W Wong; S A Richards; A de Bruyn Kops; J A Smith; J H Weis
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

7.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus.

Authors:  Emily C Baechler; Franak M Batliwalla; George Karypis; Patrick M Gaffney; Ward A Ortmann; Karl J Espe; Katherine B Shark; William J Grande; Karis M Hughes; Vivek Kapur; Peter K Gregersen; Timothy W Behrens
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-25       Impact factor: 11.205

8.  Identification of a 145,000 Mr membrane protein as the C3d receptor (CR2) of human B lymphocytes.

Authors:  J J Weis; T F Tedder; D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

9.  Identification of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody.

Authors:  K Iida; L Nadler; V Nussenzweig
Journal:  J Exp Med       Date:  1983-10-01       Impact factor: 14.307

10.  Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice.

Authors:  Marie-Laure Santiago-Raber; Roberto Baccala; Katarina M Haraldsson; Divaker Choubey; Timothy A Stewart; Dwight H Kono; Argyrios N Theofilopoulos
Journal:  J Exp Med       Date:  2003-03-17       Impact factor: 14.307

View more
  4 in total

1.  Human complement receptor type 1/CD35 is an Epstein-Barr Virus receptor.

Authors:  Javier G Ogembo; Lakshmi Kannan; Ionita Ghiran; Anne Nicholson-Weller; Robert W Finberg; George C Tsokos; Joyce D Fingeroth
Journal:  Cell Rep       Date:  2013-02-14       Impact factor: 9.423

2.  Human complement receptor 2 (CR2/CD21) as a receptor for DNA: implications for its roles in the immune response and the pathogenesis of systemic lupus erythematosus (SLE).

Authors:  Rengasamy Asokan; Nirmal K Banda; Gerda Szakonyi; Xiaojiang S Chen; V Michael Holers
Journal:  Mol Immunol       Date:  2012-08-10       Impact factor: 4.407

Review 3.  The future of crystallography in drug discovery.

Authors:  Heping Zheng; Jing Hou; Matthew D Zimmerman; Alexander Wlodawer; Wladek Minor
Journal:  Expert Opin Drug Discov       Date:  2013-12-28       Impact factor: 6.098

4.  Relative Impact of Complement Receptors CD21/35 (Cr2/1) on Scrapie Pathogenesis in Mice.

Authors:  Sarah J Kane; Eric Swanson; Elizabeth O Gordon; Savannah Rocha; Heather R Bender; Luke R Donius; Adriano Aguzzi; Jonathan P Hannan; Mark D Zabel
Journal:  mSphere       Date:  2017-11-22       Impact factor: 4.389

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.